Coherus Oncology

Attending #ESMO25? Connect with the Coherus Oncology team!

The top story this week is the 2025 Nobel Prize in physiology or medicine, recognizing discoveries concerning the importance of peripheral immune tolerance and the role T regulatory cells (Tregs) play in suppressing autoimmunity. The discovery of Tregs and their ability to silence or restrain T cells has applications in both autoimmune disease and cancer. The latest in SITC's webinar series, Targets for Cancer IO focuses on the CCR8+ Treg depletion as an emerging target for cancer. Learn more about Coherus Oncology's clinical candidate, CHS-114, a highly selective anti-CCR8 cytolytic antibody, and the translational and clinical data generated to date in this upcoming webinar: https://bit.ly/3VEkGjx

This year’s Nobel Prize in Physiology or Medicine recognizes the discovery of regulatory T cells (Tregs), immune regulators that stop immune cells and prevent autoimmunity, but also block immune cells from attacking tumors. This is an exciting moment in time for the Treg field that recognizes the potential for Treg research to transform treatment across oncology and autoimmune diseases.   At Coherus Oncology, we’re advancing this foundational biology to unlock the full anti-tumor potential of the immune system. Our lead program, CHS-114, is a selective, cytolytic anti-CCR8 antibody designed to target and deplete tumor-resident Tregs, reshape the tumor microenvironment, and boost anti-tumor immunity. CHS-114 is currently being evaluated in Phase 2a and Phase 1b studies in patients with advanced solid tumors.   Learn more about our Treg-targeted approach: https://lnkd.in/gDxHmvyV.  

Take a deep dive and explore CCR8 as a novel therapeutic target for cancer as we join Society for Immunotherapy of Cancer (SITC) for their upcoming Targets for Cancer IO: Deep Dive webinar. Our CMO, Rosh Dias, MD, MRCP, and VARUN K., PhD, will share insights from the translational research and clinical studies of CHS-114, our highly selective cytolytic anti-CCR8 mAb. To learn more about the series and register: https://bit.ly/3VEkGjx

Attending Fierce Biotech Week 2025? Don't miss the Panel: The Future of Dealmaking – What Will Matter Most in 2030 on Thursday, October 9th at 11:15 am. Coherus Oncology’s Scott Saywell will join a distinguished panel of business development leaders to discuss how deal structures, expectations, and therapeutic priorities are evolving, as well as what to prepare for over the next five years. 

Coherus Oncology is a proud supporter of the Head & Neck Cancer Alliance and its programs, including the Head & Neck Cancer Survivorship Symposium. This event brings together individuals who truly understand the impact of this disease — patients, fellow survivors, caregivers, and leading medical professionals who are dedicated to supporting this community. 

We look forward to sharing new biomarker data from our Phase 1 study of CHS-114 at the upcoming 40th Annual SITC Meeting. CHS-114 is a highly selective, cytolytic anti-CCR8 mAb designed to deplete immunosuppressive CCR8+ intratumoral Tregs and remodel the tumor microenvironment to promote antitumor immunity. Read more about our presentation and upcoming SITC webinar: https://bit.ly/3VJT1h5

Tune in tomorrow to listen to our fireside chat with David Dai at UBS’s Virtual Oncology Day. CEO, Denny Lanfear, CMO, Rosh Dias, MD, MRCP, and CSDO Theresa LaVallee, PhD will discuss the latest developments with our novel oncology pipeline targeting the immune-suppressive mechanisms in the tumor microenvironment. Listen to the webcast: https://bit.ly/4mCSzvR

Our commitment to making a difference in the lives of people with rare cancer is at the center of everything we do. Today, on September 30th, we recognize Rare Cancer Day, an initiative spearheaded by the National Organization for Rare Disorders, and are proud to share that Congress has signed the Resolution - officially recognizing this important day for the many people and their loved ones impacted by a rare cancer. We are thrilled to have led this effort with our partners at NORD and stand proudly alongside patients like Floyd and his wife Monique, whose powerful story is a reminder for all of us to drive awareness and support this community. Thank you also to Rep Kelly and his staff for their support of the Resolution and rare cancers. Read more: https://bit.ly/3ICWT0s and learn about our work at Coherus: bit.ly/3Kmdhml #PatientSupport #RareCancerDay

This year, 2 million new cancer cases are expected to be diagnosed in the US, and over one in four cancer diagnoses in the US is a rare cancer. Although progress has been made to help improve cancer care and outcomes, there remains an unmet need for significant advancements and new treatment options to make a meaningful impact on all cancer patients’ lives. At Coherus Oncology, we want to ensure that no patient faces a cancer journey alone. That’s why we partnered with The NORD Rare Cancer Coalition and Representative Kelly to introduce a resolution to recognize September 30 as Rare Cancer Day. Join us as we recognize people living with rare cancers and reaffirm our commitment to advancing efforts that drive research, enhance early diagnosis, and bring novel treatments to all patients with cancer, including those diagnosed with a rare form. Learn more about our commitment: bit.ly/3Kmdhml and Representative Kelly’s Rare Cancer Day resolution: http://bit.ly/4gJMvR8 #PatientSupport #RareCancerDay